TAS-102 Plus Bevacizumab as an Effective and Well Tolerated Regimen in Chemotherapy-Refractory Advanced Colorectal Cancers – A Single Institution Retrospective Analysis

Abstract

Objective

There are limited data on the utility of TAS-102 plus bevacizumab in patients with chemotherapy-refractory metastatic colorectal cancer (mCRC) treated in India.

Methods

Patients diagnosed with chemotherapy-refractory mCRC, defined as having received at least prior oxaliplatin and irinotecan–based chemotherapy between January 2017 and January 2022, and who began treatment with a combination of TAS-102 and bevacizumab were retrospectively analyzed for demographic variables, survivals, and prognostic parameters. The primary endpoint of the study was estimation of the median overall survival (OS) by the Kaplan–Meier method.

Results

The data of 143 patients satisfied the prespecified inclusion criteria and were included for analysis. There was a predominance of left-sided CRCs (78%) and patients having greater than two sites of distant metastases (87%), with 41% of patients with at least two lines of prior therapy. With a median follow-up of 11.6 months, the median OS of the entire cohort was 10.9 months, while the median progression-free survival was 4.4 months. The combination was well tolerated, with the most common grade 3/4 side effects being neutropenia (25%), anemia (6%), and thrombocytopenia (4%). Dose modifications in TAS-102 were required in 20% of patients, though this did not entail permanent cessation of TAS-102 in any patient. The presence of a resected primary was prognostic for improved OS (p < 0.001), while signet ring histology predicted inferior OS (p < 0.001).

Conclusion

The combination of TAS-102 and bevacizumab is an efficacious and safe therapeutic option in patients with mCRC who have received at least two lines of prior systemic therapy. There were no requirements for cessation of the combination in the current study, underlying the well-tolerated nature of the combination.

Keywords

bevacizumab - chemotherapy-refractory colorectal cancer - TAS-102 - tipiracil - trifluridine

Publication History

Received: 25 August 2024

Accepted: 28 November 2024

Article published online:
07 January 2025

• References

• 1 Sung H, Ferlay J, Siegel RL. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71 (03) 209-249
• 2 Asthana S, Khenchi R, Labani S. Incidence of colorectal cancers in India: A review from population-based cancer registries. Curr Med Res Pract 2021; 11 (02) 91
• 3 Mathew Thomas V, Baby B, Wang K. et al. Trends in colorectal cancer incidence in India. J Clin Oncol 2020; 38 (15) e16084-e16084
• 4 Patil PS, Saklani A, Gambhire P. et al. Colorectal cancer in India: an audit from a tertiary center in a low prevalence area. Indian J Surg Oncol 2017; 8 (04) 484-490
• 5 Ramaswamy A, Babu V, Kothari R. et al. Treatment of metastatic colorectal cancers in resource-constrained low- and middle-income countries (LMICS) scenario-outcomes, practice patterns, and commentary on treatment costs. South Asian J Cancer 2022; 11 (04) 293-298
• 6 Cervantes A, Adam R, Roselló S. et al; ESMO Guidelines Committee. Electronic address: [e-mail]. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol 2023; 34 (01) 10-32
• 7 Sharma V, Sharma A, Raina V. et al. Metastatic colo-rectal cancer: real life experience from an Indian tertiary care center. BMC Cancer 2021; 21 (01) 630
• 8 André T, Shiu KK, Kim TW. et al; KEYNOTE-177 Investigators. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med 2020; 383 (23) 2207-2218
• 9 Trikha M, Sarkar L, Dhanawat A. et al. Performance of low-dose immunotherapy and standard-dose immunotherapy in microsatellite instability-high metastatic colorectal cancer: real-world data (CLouD-high study). JCO Glob Oncol 2024; 10 (10) e2400141
• 10 Mayer RJ, Van Cutsem E, Falcone A. et al; RECOURSE Study Group. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 2015; 372 (20) 1909-1919
• 11 Li J, Qin S, Xu R. et al; CONCUR Investigators. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2015; 16 (06) 619-629
• 12 Prager GW, Taieb J, Fakih M. et al; SUNLIGHT Investigators. Trifluridine-tipiracil and bevacizumab in refractory metastatic colorectal cancer. N Engl J Med 2023; 388 (18) 1657-1667
• 13 Dasari A, Lonardi S, Garcia-Carbonero R. et al; FRESCO-2 Study Investigators. Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. Lancet 2023; 402 (10395): 41-53
• 14 Ramaswamy A, Ostwal V, Pande N. et al. Practice patterns and outcomes with the use of regorafenib in metastatic colorectal cancer: results from the regorafenib in metastatic colorectal cancer: an Indian exploratory analysis study. South Asian J Cancer 2020; 08: 22-26
• 15 Su GL, Wang YY, Wang JC, Liu H. A meta-analysis comparing regorafenib with TAS-102 for treating refractory metastatic colorectal cancer. J Int Med Res 2020; 48 (07) 300060520926408
• 16 Abrahao ABK, Ko YJ, Berry S, Chan KKW. A comparison of regorafenib and TAS-102 for metastatic colorectal cancer: a systematic review and network meta-analysis. Clin Colorectal Cancer 2018; 17 (02) 113-120
• 17 Fujii H, Matsuhashi N, Kitahora M. et al. Bevacizumab in combination with TAS-102 improves clinical outcomes in patients with refractory metastatic colorectal cancer: a retrospective study. Oncologist 2020; 25 (03) e469-e476
• 18 Kagawa Y, Shinozaki E, Okude R, Tone T, Kunitomi Y, Nakashima M. Real-world evidence of trifluridine/tipiracil plus bevacizumab in metastatic colorectal cancer using an administrative claims database in Japan. ESMO Open 2023; 8 (04) 101614
• 19 Van Cutsem E, Danielewicz I, Saunders MP. et al. Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study. Ann Oncol 2020; 31 (09) 1160-1168
• 20 Ostwal V, Kapoor A, Engineer R. et al. Systemic chemotherapy and short-course radiation in metastatic rectal cancers: a feasible paradigm in unresectable and potentially resectable cancers. South Asian J Cancer 2019; 8 (02) 92-97
• 21 Ostwal V, Pande NS, Engineer R. et al. Low prevalence of deficient mismatch repair (dMMR) protein in locally advanced rectal cancers (LARC) and treatment outcomes. J Gastrointest Oncol 2019; 10 (01) 19-29
• 22 Huang Y, Ge K, Fu G, Chu J, Wei W. Efficacy of primary tumor resection in metastatic colorectal cancer. Med Sci Monit 2020; 26: e923501
• 23 Kanemitsu Y, Shitara K, Mizusawa J. et al; JCOG Colorectal Cancer Study Group. Primary tumor resection plus chemotherapy versus chemotherapy alone for colorectal cancer patients with asymptomatic, synchronous unresectable metastases (JCOG1007; iPACS): a randomized clinical trial. J Clin Oncol 2021; 39 (10) 1098-1107